Abstract |
In the Familial Atherosclerosis Treatment Study ( FATS), the reduction in clinical events (75%) far outweighed the modest frequency and magnitude of lesion regression observed among those receiving intensive lipid-lowering therapy. To understand this result, the disruptive changes in plaque that trigger clinical events ( cardiac death, myocardial infarction, unstable angina) are described. Data are presented in support of the idea that the clinical benefits of lipid-lowering therapy are best explained by stabilization, by depletion of lipid, of the "dangerous" subpopulation of lipid-rich plaques that are often associated with only mild or moderate coronary narrowing.
|
Authors | B G Brown, X Q Zhao, D E Sacco, J J Albers |
Journal | Annual review of medicine
(Annu Rev Med)
Vol. 44
Pg. 365-76
( 1993)
ISSN: 0066-4219 [Print] United States |
PMID | 8476257
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
|
Chemical References |
- Dietary Fats
- Hypolipidemic Agents
- Lipids
|
Topics |
- Coronary Artery Disease
(blood, pathology, physiopathology, prevention & control, therapy)
- Coronary Vessels
(pathology)
- Dietary Fats
(administration & dosage)
- Humans
- Hypolipidemic Agents
(therapeutic use)
- Lipids
(administration & dosage, blood)
- Remission Induction
|